14507922|t|Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity.
14507922|a|In previous studies we found that overexpression of the inducible form of cyclooxygenase, COX-2, in the brain exacerbated beta-amyloid (A beta) neuropathology in a transgenic mouse model of Alzheimer's disease. To explore the mechanism through which COX may influence A beta amyloidosis, we used an adenoviral gene transfer system to study the effects of human (h)COX-1 and hCOX-2 isoform expression on A beta peptide generation. We found that expression of hCOXs in human amyloid precursor protein (APP)-overexpressing (Chinese hamster ovary (CHO)-APPswe) cells or human neuroglioma (H4-APP751) cells resulting in 10-25 nM prostaglandin (PG)-E2 concentration in the conditioned medium coincided with an approximately 1.8-fold elevation of A beta-(1-40) and A beta-(1-42) peptide generation and an approximately 1.8-fold induction of the C-terminal fragment (CTF)-gamma cleavage product of the APP, an index of gamma-secretase activity. Treatment of APP-overexpressing cells with the non-selective COX inhibitor ibuprofen (1 microM, 48 h) or with the specific gamma-secretase inhibitor L-685,458 significantly attenuated hCOX-1- and hCOX-2-mediated induction of A beta peptide generation and CTF-gamma cleavage product formation. Based on this evidence, we next tested the hypothesis that COX expression might promote A beta peptide generation via a PG-E2-mediated mechanism. We found that exposure of CHO-APPswe or human embryonic kidney (HEK-APPswe) cells to PG-E2 (11-deoxy-PG-E2) at a concentration (10 nM) within the range of PG-E2 found in hCOX-expressing cells similarly promoted (approximately 1.8-fold) the generation of the CTF-gamma cleavage product of APP and commensurate A beta-(1-40) and A beta-(1-42) peptide elevation. The study suggests that expression of COXs may influence A beta peptide generation through mechanisms that involve PG-E2-mediated potentiation of gamma-secretase activity, further supporting a role for COX-2 and COX-1 in Alzheimer's disease neuropathology.
14507922	0	22	Cyclooxygenase (COX)-2	Gene	4513
14507922	27	32	COX-1	Gene	4512
14507922	44	64	beta-amyloid peptide	Gene	351
14507922	224	229	COX-2	Gene	17709
14507922	270	276	A beta	Gene	11820
14507922	309	314	mouse	Species	10090
14507922	324	343	Alzheimer's disease	Disease	MESH:D000544
14507922	402	420	A beta amyloidosis	Disease	MESH:D000686
14507922	489	494	human	Species	9606
14507922	498	503	COX-1	Gene	4512
14507922	508	514	hCOX-2	Gene	5743
14507922	601	606	human	Species	9606
14507922	607	632	amyloid precursor protein	Gene	351
14507922	655	676	Chinese hamster ovary	CellLine	CVCL:0213
14507922	678	681	CHO	CellLine	CVCL:0213
14507922	683	689	APPswe	CellLine	CVCL:D650
14507922	700	705	human	Species	9606
14507922	706	717	neuroglioma	Disease	
14507922	719	728	H4-APP751	CellLine	CVCL:D601
14507922	758	779	prostaglandin (PG)-E2	Chemical	MESH:D015232
14507922	1146	1155	ibuprofen	Chemical	MESH:D007052
14507922	1220	1229	L-685,458	Chemical	MESH:C410009
14507922	1267	1273	hCOX-2	Gene	5743
14507922	1326	1335	CTF-gamma	Gene	351
14507922	1536	1539	CHO	CellLine	CVCL:0213
14507922	1540	1546	APPswe	CellLine	CVCL:D650
14507922	1550	1555	human	Species	9606
14507922	1574	1584	HEK-APPswe	CellLine	CVCL:A5CZ
14507922	1595	1600	PG-E2	Chemical	MESH:D015232
14507922	1602	1616	11-deoxy-PG-E2	Chemical	-
14507922	1665	1670	PG-E2	Chemical	MESH:D015232
14507922	1768	1777	CTF-gamma	Gene	351
14507922	1985	1990	PG-E2	Chemical	MESH:D015232
14507922	2072	2077	COX-2	Gene	4513
14507922	2082	2087	COX-1	Gene	4512
14507922	2091	2110	Alzheimer's disease	Disease	MESH:D000544
14507922	Positive_Correlation	11820	17709
14507922	Positive_Correlation	351	4512
14507922	Negative_Correlation	MESH:C410009	351
14507922	Negative_Correlation	MESH:D007052	351
14507922	Positive_Correlation	351	5743
14507922	Positive_Correlation	MESH:D015232	351
14507922	Negative_Correlation	MESH:C410009	5743
14507922	Negative_Correlation	MESH:D007052	5743
14507922	Positive_Correlation	351	4513

